Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Free Cash Flow (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Free Cash Flow for 7 consecutive years, with -$56.5 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 71.01% to -$56.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$447.0 million through Dec 2025, up 14.2% year-over-year, with the annual reading at -$447.0 million for FY2025, 14.2% up from the prior year.
  • Free Cash Flow hit -$56.5 million in Q4 2025 for BridgeBio Pharma, up from -$110.6 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $74.7 million in Q2 2024 to a low of -$219.6 million in Q1 2024.
  • Historically, Free Cash Flow has averaged -$121.0 million across 5 years, with a median of -$128.4 million in 2021.
  • Biggest five-year swings in Free Cash Flow: plummeted 245.12% in 2023 and later skyrocketed 165.88% in 2024.
  • Year by year, Free Cash Flow stood at -$123.7 million in 2021, then rose by 20.8% to -$98.0 million in 2022, then dropped by 28.5% to -$125.9 million in 2023, then plummeted by 54.62% to -$194.7 million in 2024, then skyrocketed by 71.01% to -$56.5 million in 2025.
  • Business Quant data shows Free Cash Flow for BBIO at -$56.5 million in Q4 2025, -$110.6 million in Q3 2025, and -$80.7 million in Q2 2025.